Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H16ClN3O |
Molecular Weight | 313.781 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC2=C(OC3=C(C=CC=C3)N=C2N4CCNCC4)C=C1
InChI
InChIKey=QWGDMFLQWFTERH-UHFFFAOYSA-N
InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2
Molecular Formula | C17H16ClN3O |
Molecular Weight | 313.781 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Amoxapine is an antidepressant of the dibenzoxazepine class, chemically distinct from the dibenzazepines, dibenzocycloheptenes, and dibenzoxepines. It is designated chemically as 2-Chloro-11- (1-piperazinyl)dibenz[b,f ][1,4]oxazepine. Amoxapine is an antidepressant with a mild sedative component to its action. The mechanism of its clinical action in man is not well understood. In animals, amoxapine reduced the uptake of norepinephrine and serotonin and blocked the response of dopamine receptors to dopamine. Amoxapine is not a monoamine oxidase inhibitor. Amoxapine is absorbed rapidly and reaches peak blood levels approximately 90 minutes after ingestion. It is almost completely metabolized. The main route of excretion is the kidney. In vitro tests show that amoxapine binding to human serum is approximately 90%. In man, amoxapine serum concentration declines with a half-life of eight hours. However, the major metabolite, 8-hydroxyamoxapine, has a biologic half-life of 30 hours. Metabolites are excreted in the urine in conjugated form as glucuronides. Clinical studies have demonstrated that amoxapine has a more rapid onset of action than either amitriptyline or imipramine. The initial clinical effect may occur within four to seven days and occurs within two weeks in over 80% of responders.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2096905 |
|||
Target ID: CHEMBL222 |
|||
Target ID: CHEMBL228 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15655900 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | AMOXAPINE Approved UseAmoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation. Launch Date7.1487357E11 |
|||
Primary | AMOXAPINE Approved UseAmoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation. Launch Date7.1487357E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
33.55 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3997304/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMOXAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
319 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3997304/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMOXAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.02 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3997304/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMOXAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3997304/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMOXAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Doses
Dose | Population | Adverse events |
---|---|---|
300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Other AEs: Ataxia, Drowsiness... Other AEs: Ataxia (>1) Sources: Drowsiness (14%) Dry mouth (14%) Constipation (12%) Blurred vision (7%) Anxiety (>1) Insomnia (>1) Nervousness (>1) Nightmare (>1) Restlessness (>1) Palpitations (>1) Tremor (>1) Confusion (>1) Excitement (>1) Edema (>1) Skin rash (>1) Prolactin increased (>1) Nausea (>1) Dizziness (>1) Headache (>1) Fatigue (>1) Weakness (>1) Appetite excessive (>1) Perspiration excessive (>1) Accommodation disturbance (<1%) Mydriasis (<1%) Micturition disorder (<1%) Urinary retention (<1%) Nasal stuffiness (<1%) Hypotension (<1%) Hypertension (<1%) Syncope (<1%) Tachycardia (<1%) Drug fever (<1%) Urticaria (<1%) Photosensitized (<1%) Pruritus (<1%) Vasculitis (<1%) Hepatitis (<1%) Tingling (<1%) Tinnitus (<1%) Disorientation (<1%) Seizures (<1%) Hypomania (<1%) Numbness (<1%) Incoordination (<1%) Concentration impairment (<1%) Hyperthermia (<1%) Extrapyramidal symptoms (<1%) Tardive dyskinesia (<1%) Leukopenia (<1%) Agranulocytosis (<1%) Epigastric distress (<1%) Vomiting (<1%) Flatulence (<1%) Abdominal pain (<1%) Taste peculiar (<1%) Diarrhea (<1%) Impotence (<1%) Menstrual irregularity (<1%) Breast enlargement (<1%) Inappropriate antidiuretic hormone secretion (<1%) Galactorrhea (<1%) Lacrimation (<1%) Weight gain (<1%) Weight loss (<1%) Impaired liver function (<1%) Painful ejaculation (<1%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Constipation | 12% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Drowsiness | 14% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Dry mouth | 14% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Blurred vision | 7% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Abdominal pain | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Accommodation disturbance | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Agranulocytosis | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Breast enlargement | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Concentration impairment | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Diarrhea | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Disorientation | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Drug fever | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Epigastric distress | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Extrapyramidal symptoms | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Flatulence | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Galactorrhea | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Hepatitis | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Hypertension | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Hyperthermia | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Hypomania | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Hypotension | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Impaired liver function | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Impotence | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Inappropriate antidiuretic hormone secretion | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Incoordination | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Lacrimation | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Leukopenia | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Menstrual irregularity | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Micturition disorder | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Mydriasis | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Nasal stuffiness | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Numbness | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Painful ejaculation | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Photosensitized | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Pruritus | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Seizures | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Syncope | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Tachycardia | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Tardive dyskinesia | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Taste peculiar | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Tingling | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Tinnitus | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Urinary retention | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Urticaria | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Vasculitis | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Vomiting | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Weight gain | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Weight loss | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Anxiety | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Appetite excessive | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Ataxia | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Confusion | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Dizziness | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Edema | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Excitement | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Fatigue | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Headache | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Insomnia | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Nausea | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Nervousness | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Nightmare | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Palpitations | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Perspiration excessive | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Prolactin increased | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Restlessness | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Skin rash | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Tremor | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Weakness | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Amoxapine-associated acute renal failure. | 1985 Jun |
|
Chronic but not acute treatment with antidepressants enhances the electroconvulsive seizure response in rats. | 1985 Oct |
|
Serum neuroleptic levels and extrapyramidal side effects in patients treated with amoxapine. | 1985 Oct |
|
Amoxapine-induced extrapyramidal effects. | 1986 Jun |
|
Amoxapine-induced cognitive impairment in two patients. | 1987 Apr |
|
Acute myocardial failure following amoxapine intoxication. | 1988 Feb |
|
Biochemical evidence that high concentrations of the antidepressant amoxapine may cause inhibition of mitochondrial electron transport. | 1988 Mar 30 |
|
[A case of amoxapine-induced tardive dystonia successfully treated with a low dose anti-cholinergic agent]. | 2000 Apr |
|
A case of neuroleptic malignant syndrome in a patient with hemodialysis. | 2000 Feb |
|
Meta-analytical studies on new antidepressants. | 2001 |
|
Availability of learned helplessness test as a model of depression compared to a forced swimming test in rats. | 2001 |
|
Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. | 2001 Dec 27 |
|
Depressive disorders preceding temporal lobe epilepsy. | 2002 Apr |
|
[Unexpected drug-interaction]. | 2002 Feb |
|
The clinical pharmacology of depressive states. | 2002 Mar |
|
Effects of some antidepressant drugs on tryptaminergic responses of the rat jejunum. | 2003 Oct |
|
Biological pathophysiology of mood disorders special reference to the neurotransmitter receptors. | 2004 |
|
Amoxapine in schizophrenia: a negative double-blind controlled trial. | 2004 Aug |
|
A novel physiological mechanism of glycine-induced immunomodulation: Na+-coupled amino acid transporter currents in cultured brain macrophages. | 2004 Aug 15 |
|
Possible serotonin syndrome arising from an interaction between caffeine and serotonergic antidepressants. | 2004 Jul |
|
Intrathecal tri-cyclic antidepressants produce spinal anesthesia. | 2004 Nov |
|
Bergmann glial GlyT1 mediates glycine uptake and release in mouse cerebellar slices. | 2004 Nov 1 |
|
Amoxapine as an atypical antipsychotic: a comparative study vs risperidone. | 2005 Dec |
|
Remarkable effect of selegiline (L-deprenyl), a selective monoamine oxidase type-B inhibitor, in a patient with severe refractory depression: a case report. | 2005 Jul-Aug |
|
Treatments in depression. | 2006 |
|
[Treatment for irritable bowel syndrome--psychotropic drugs, antidepressants and so on]. | 2006 Aug |
|
Simultaneous analysis of haloperidol, its three metabolites and two other butyrophenone-type neuroleptics by high performance liquid chromatography with dual ultraviolet detection. | 2006 Feb |
|
Novel two-stage screening procedure leads to the identification of a new class of transfection enhancers. | 2006 Jun |
|
Solid-phase extraction and analysis of 20 antidepressant drugs in human plasma by LC/MS with SSI method. | 2006 Oct 16 |
|
Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis. | 2007 Jul 26 |
|
A fatal case of amoxapine poisoning under the influence of chronic use of psychotropic drugs. | 2007 Mar |
|
Differential distribution of glycine transporters in Müller cells and neurons in amphibian retinas. | 2007 Mar-Apr |
|
Prevalence and predictors of antidepressant use in a cohort of pregnant women. | 2007 Sep |
|
Depression following thrombotic cardiovascular events in elderly medicare beneficiaries: risk of morbidity and mortality. | 2009 |
|
5-Hydroxytryptamine Receptor Subtypes and their Modulators with Therapeutic Potentials. | 2009 Jun |
|
Persistence and compliance to antidepressant treatment in patients with depression: a chart review. | 2009 Jun 16 |
|
Amoxapine-induced tardive dyskinesia. | 2009 Oct-Dec |
|
Syndrome of inappropriate secretion of anti-diuretic hormone in an elderly depressive patient receiving paroxetine: a case report. | 2010 Apr |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
Validation of HPLC-MS/MS methods for analysis of loxapine, amoxapine, 7-OH-loxapine, 8-OH-loxapine and loxapine N-oxide in human plasma. | 2010 Dec |
|
Amoxapine inhibits the delayed rectifier outward K+ current in mouse cortical neurons via cAMP/protein kinase A pathways. | 2010 Feb |
|
A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle. | 2010 Feb 23 |
|
Hallucinations: Clinical aspects and management. | 2010 Jan |
|
Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes. | 2010 Jan |
|
Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database. | 2010 Mar |
|
Gene expression profile analysis of genes in rat hippocampus from antidepressant treated rats using DNA microarray. | 2010 Nov 30 |
|
Tricyclic antidepressants and headaches: systematic review and meta-analysis. | 2010 Oct 20 |
|
Inhibition of G protein-activated inwardly rectifying K+ channels by different classes of antidepressants. | 2011 |
|
In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine. | 2011 Oct |
Sample Use Guides
Usual effective dosage is 200 to 300 mg daily. Three weeks constitutes an adequate period of trial providing dosage has reached 300 mg daily (or lower level of tolerance) for at least two weeks. If no response is seen at 300 mg, dosage may be increased, depending upon tolerance, up to 400 mg daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19915071
Cells (mouse cortical neurons) were incubated with or without amoxapine varying concentrations of 10, 50, and 100 uM. At a concentration of 10 to 500 uM, amoxapine reversibly inhibited I(K) in a dose-dependent manner and modulated both steady-state activation and inactivation properties.
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 02:08:32 UTC 2023
by
admin
on
Thu Jul 06 02:08:32 UTC 2023
|
Record UNII |
R63VQ857OT
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN06AA17
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
||
|
NDF-RT |
N0000175752
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
||
|
WHO-ATC |
N06AA17
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
||
|
LIVERTOX |
NBK548520
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
||
|
NCI_THESAURUS |
C94727
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
191
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
PRIMARY | |||
|
SUB05479MIG
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
PRIMARY | |||
|
Amoxapine
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
PRIMARY | |||
|
722
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
PRIMARY | RxNorm | ||
|
R63VQ857OT
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
PRIMARY | |||
|
14028-44-5
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
PRIMARY | |||
|
1031401
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
PRIMARY | |||
|
201
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
PRIMARY | |||
|
M1843
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
PRIMARY | Merck Index | ||
|
2675
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
PRIMARY | |||
|
237-867-1
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
PRIMARY | |||
|
3049
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
PRIMARY | |||
|
DB00543
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
PRIMARY | |||
|
759559
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
PRIMARY | |||
|
DTXSID7022598
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
PRIMARY | |||
|
Amoxapine
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
PRIMARY | |||
|
R63VQ857OT
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
PRIMARY | |||
|
2170
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
PRIMARY | |||
|
D000657
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
PRIMARY | |||
|
CHEMBL1113
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
PRIMARY | |||
|
100000087430
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
PRIMARY | |||
|
C47397
Created by
admin on Thu Jul 06 02:08:32 UTC 2023 , Edited by admin on Thu Jul 06 02:08:32 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
PARENT -> METABOLITE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||